The Anti-Proliferative Effect of Genistein on Antioxidant System, Cell Proliferation, and Apoptosis: Implications for Hormone- Refractory Prostate Cancer Therapy
Abstract
Objectives: This study aims to examine the effect of different genistein concentrations on apoptosis, estrogen receptor beta, and manganese superoxide dismutase (MnSOD) protein expressions in PC3 hormone-resistant metastatic prostate cancer cell lines.
Materials and Methods: Genistein concentrations of 0, 0.01, 0.1, 0.5, 1, 5, 10, and and 50 μM were applied to PC3 hormone-resistant metastatic prostate cancer cell lines for 48 hours and water soluble tetrazolium salt-1 cell proliferation assay was performed. Protein was extracted from the cells and cleaved poly (ADP-ribose) polymerase, estrogen receptor beta (ERβ), and MnSOD protein expression levels were examined using the Western blot protocol. One-way analysis of variance (ANOVA) and Student’s t-test statistical analysis methods were applied to determine whether there are statistically significant differences.
Results: Genistein was found to change ERβ expression in PC3 cells depending on concentration. While ERβ protein expression increases observed at low concentrations (0.01-0.5 μM), it sometimes decreased to baseline or increased modestly at high concentrations (1-50 μM). MnSOD protein expression showed a stimulating effect on the protein expression level at high concentrations (1-50 μM).
Conclusion: This research study investigates how different concentrations of genistein affect cell proliferation, apoptosis, estrogen receptor beta, and MnSOD protein expression levels in PC3 hormone-refractory prostate cancer cells.
Keywords
Prostate cancer, genistein, apoptosis, ERβ, MnSOD
Ethical Statement
Ethics Committee Approval: The cells used in the study are commercially available, so ethics committee approval is not required.
References
- 1. Carlsson SV, Vickers AJ. Screening for prostate cancer. Med Clin North Am. 2020;104:1051-1062.
- 2. Feldman B, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45.
- 3. Macedo-Silva C, Benedetti R, Ciardiello F, et al. Epigenetic mechanisms underlying prostate cancer radioresistance. Clin Epigenet. 2021;13:125.
- 4. Ramírez-de-Arellano A, Pereira-Suárez AL, Rico-Fuentes C, et al. Distribution and effects of estrogen receptors in prostate cancer: associated molecular mechanisms. Front Endocrinol (Lausanne). 2022;12:811578.
- 5. Spagnuolo C, Russo GL, Bilotto S, et al. Genistein and cancer: current status, challenges, and future directions. Advances in Nutrition. 2015;6:408-419.
- 6. Li Y, Ahmed F, Ali S, et al. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Research. 2005;65:6934-6942.
- 7. Tuli HS, Tuorkey MJ, Thakral F, et al. Molecular mechanisms of action of genistein in cancer: recent advances. Front Pharmacol. 2019;10:1336.
- 8. Di Zazzo E, Galasso G, Giovannelli P, et al. Estrogens and their receptors in prostate cancer: therapeutic implications. Front Oncol. 2018;8:2.
- 9. Sharifi-Rad J, Quispe C, Imran M, et. al. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid Med Cell Longev. 2021;2021:3268136.
- 10. Liu M, Sun X, Chen B, et. al. Insights into manganese superoxide dismutase and human diseases. Int J Mol Sci. 2022;23:15893.